

**Anti-Siglec-3 / CD33 Reference Antibody (vadastuximab talirine)  
Recombinant Antibody  
Catalog # APR10746**

**Specification**

---

**Anti-Siglec-3 / CD33 Reference Antibody (vadastuximab talirine) - Product Information**

Application	FC, E, FTA
Primary Accession	<a href="#">P20138</a>
Reactivity	Cynomolgus, Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	145 KDa

**Anti-Siglec-3 / CD33 Reference Antibody (vadastuximab talirine) - Additional Information**

**Target/Specificity**  
Siglec-3 / CD33

**Endotoxin**  
< 0.001EU/ µg,determined by LAL method.

**Conjugation**  
PBD

**Expression system**  
CHO Cell

**Format**  
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

**Storage**  
-80°C for 2 years under sterile conditions □ -20°C for 1 year under sterile conditions □ Avoid repeated freeze-thaw cycles.

**Anti-Siglec-3 / CD33 Reference Antibody (vadastuximab talirine) - Protein Information**

**Name** CD33

**Synonyms** SIGLEC3

**Function**  
Sialic-acid-binding immunoglobulin-like lectin (Siglec) that plays a role in mediating cell-cell interactions and in maintaining immune cells in a resting state (PubMed:<a href="http://www.uniprot.org/citations/10611343" target="\_blank">10611343</a>, PubMed:<a href="http://www.uniprot.org/citations/11320212" target="\_blank">11320212</a>, PubMed:<a href="http://www.uniprot.org/citations/15597323" target="\_blank">15597323</a>). Preferentially recognizes and binds alpha-2,3- and more avidly alpha-2,6-linked sialic acid-bearing glycans

(PubMed:<a href="http://www.uniprot.org/citations/7718872" target="\_blank">7718872</a>). Upon engagement of ligands such as C1q or sialylated glycoproteins, two immunoreceptor tyrosine-based inhibitory motifs (ITIMs) located in CD33 cytoplasmic tail are phosphorylated by Src-like kinases such as LCK (PubMed:<a href="http://www.uniprot.org/citations/10887109" target="\_blank">10887109</a>, PubMed:<a href="http://www.uniprot.org/citations/28325905" target="\_blank">28325905</a>). These phosphorylations provide docking sites for the recruitment and activation of protein-tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-2 (PubMed:<a href="http://www.uniprot.org/citations/10206955" target="\_blank">10206955</a>, PubMed:<a href="http://www.uniprot.org/citations/10556798" target="\_blank">10556798</a>, PubMed:<a href="http://www.uniprot.org/citations/10887109" target="\_blank">10887109</a>). In turn, these phosphatases regulate downstream pathways through dephosphorylation of signaling molecules (PubMed:<a href="http://www.uniprot.org/citations/10206955" target="\_blank">10206955</a>, PubMed:<a href="http://www.uniprot.org/citations/10887109" target="\_blank">10887109</a>). One of the repressive effect of CD33 on monocyte activation requires phosphoinositide 3-kinase/PI3K (PubMed:<a href="http://www.uniprot.org/citations/15597323" target="\_blank">15597323</a>).

### Cellular Location

[Isoform CD33M]: Cell membrane; Single-pass type I membrane protein

### Tissue Location


Monocytic/myeloid lineage cells. In the brain, CD33 is mainly expressed on microglial cells

## Anti-Siglec-3 / CD33 Reference Antibody (vadastuximab talirine) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

## Anti-Siglec-3 / CD33 Reference Antibody (vadastuximab talirine) - Images



Anti-Siglec-3 / CD33 Reference Antibody (vadastuximab talirine) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%



The purity of Anti-Siglec-3 / CD33 Reference Antibody (vadastuximab talirine) is more than 95% ,determined by SEC-HPLC.